ILLIMIS THERAPEUTICS
A company that constantly takes on challenges to translate cutting-edge science into medicines for incurable disease based on fusion protein platform technologies.
- NO. OF EMPLOYEE
-
40
14 Ph.D.
- LOCATIONS
-
SEOUL, KOREA
BOSTON, USA
- ACHIEVEMENTS
-
-
PUBLICATION & PATENT
Published in Nature Medicine GAIA platform technology
Total of 7 patent families filed
GAIA Platform patent granted across 3 countries (US·KR·RU) -
GRANT
2020 Korea Dementia Research Center (KDRC) Total of 0.8M USD/ 3 years
TIPS (Tech Incubator Program For Startup Korea) Total of 0.4M USD/ 2 years
Industry-Research Institute Collaboration Platform Total of 0.2M USD/ 2 years
2022 Baby Unicorn Company of Korea by Ministry of SMEs and Startups
2023 Scale Up TIPS Total of 0.8M USD/ 3 years
2025 Korea Dementia Research Center(KDRC) Total of 1.14M USD/ 3 years
2025 Deeptech Incubator Project for Startup(DIPS) 1000+ Total of 0.4M USD/ 3 years
2025 Global Collaborative R&D Total of 1.1M USD/ 3 years
Pre-Unicorn Startup for 2025 of Korea by Ministry of SMEs and Startups
-
CONFERENCE
Oral Presentation at 2022 AD/PD (Spain)
Oral Presentation at 2022 Keystone Symposia (US)
Oral Presentation at 2025 AAIC (Canada)
-
- FOUNDATION
-
2021
- FUND RAISING
-
66.4 Million USD
Last updated : September 2025
CO-FOUNDERS
-
- Sanghoon Park,
President & CEO - Co-founder
- Sanghoon Park,
-
- Wonsuk Chung,
Professor -
Scientific Co-founder
Department of Biological Sciences
KAIST
- Wonsuk Chung,
-
- Chanhyuk Kim,
Professor -
Scientific Co-founder
School of Transdisciplinary Innovations
Seoul National University
- Chanhyuk Kim,
FOUNDER’S STORY
